ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anthracycline
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anthracycline
37
trial(s) found.
NCT06815575
Advanced
Phase 1
Recruiting
A Two-part Phase 1 Open-label Safety and Pharmacokinetic Study of Intravenous RC220 in Combination With Doxorubicin in Adult Patients With Solid Tumours. (
RAC-010
)
anthracycline
antimetabolite
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2259 - Wyong - Wyong Hospital
NCT06564038
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
+ anthracycline
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Leukaemia
Mantle cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06486441
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (
ASCENT-GYN-01
)
anti-Trop2 antibody-drug conjugate
+ anthracycline
Endometrial cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT06356129
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (
GOLSEEK-1
)
CELMoD agent
placebo
+ anthracycline
Diffuse large B-cell lymphoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06312176
Advanced
Phase 3
Recruiting
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (
2870-010
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
+ anthracycline
Breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06203210
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (
IDeate-Lung02
)
anti-B7H3 antibody-drug conjugate
+ anthracycline
Small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06132958
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095) (
TroFuse-005
)
anti-Trop2 antibody-drug conjugate
+ anthracycline
Endometrial cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06112379
Curative
Phase 3
Recruiting
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (
D926QC00001
; TROPION-Breast04)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
+ anthracycline
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
VIC
3002 - East Melbourne - Epworth Freemasons
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)
NCT06072781
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (
RAMP-301
)
FAK inhibitor
RAF/MEK clamp
+ anthracycline
Low-grade serous ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06047080
Haem
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (
GO44145
)
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
anti-CD79b antibody-drug conjugate
bispecific T-cell engager,CD20-targeting
glucocorticoid
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05870748
Advanced
Phase 2 / Phase 3
Recruiting
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) (
STRO-002-GM3
)
anti-FR-alpha antibody-drug conjugate
+ anthracycline
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
Platinum resistant ovarian cancer
Primary peritoneal serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05605899
Haem
Phase 3
Recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (
ZUMA-23
)
autologous CAR-T-cell therapy,CD19-targeting
+ anthracycline
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05453903
Haem
Phase 1
Recruiting
A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations (
CR109124
)
KMT2A inhibitor
+ anthracycline
Acute myeloid leukaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT04884035
Haem
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
cereblon modulator
+ anthracycline
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
WA
6000 - Perth - Royal Perth Hospital (COMPLETED)
NCT04759586
Haem
Phase 3
Recruiting
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (
NCI-2021-01071
)
anti-PD-1 monoclonal antibody
+ anthracycline
Diffuse large B-cell lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04623541
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
+ anthracycline
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
NCT04516447
Advanced
Phase 1
Recruiting
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer (
ZN-c3-002
)
WEE1 inhibitor
anti-VEGF monoclonal antibody
+ anthracycline
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
VIC
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
+ anthracycline
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04322318
Advanced
Phase 2
Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (
AREN1921
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Radiotherapy
Topotecan
Vincristine
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ anthracycline
Wilms tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre (SUSPENDED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04221035
Advanced
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ anthracycline
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT04106492
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors (
SQ3370-001
)
anthracycline
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04031677
Curative
Phase 3
Recruiting
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) (
STRASS2
)
Dacarbazine
Doxorubicin
Epirubicin
Ifosfamide
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
+ anthracycline
Leiomyosarcoma
Liposarcoma
Peritoneal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
AALL1732
)
anti-CD22 antibody-drug conjugate
+ anthracycline
Acute lymphoblastic leukaemia
Leukaemia
Lymphoma
Mixed phenotype acute leukaemia
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12624000532505
Advanced
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ anthracycline
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12623000174684
Advanced
Phase 1
Recruiting
A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer (
APG2449OG101
)
ALK inhibitor,third generation
FAK/ALK/ROS1 inhibitor
FAK inhibitor
anthracycline
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
+ anthracycline
B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12619001656123
Haem
Phase 1
Not yet recruiting
Clarifying the role of early application of CAR T cells in Primary refractory and early relapsed diffuse large B cell lymphoma patients. (
CLARIFY-NHL34
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Fludarabine
Ifosfamide
Mesna
Prednisolone
Rituximab
Vincristine
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
sodium mercaptoethanesulfonate
topoisomerase inhibitor
vinca alkaloid
+ anthracycline
Diffuse large B-cell lymphoma
ACTRN12619001031156
Haem
Phase 3
Recruiting
AMLM23- placebo-controlled study to compare the event free survival of patients receiving ivosidenib or enasidenib in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. (
HOVON150-AMLSG29-18
)
IDH1 R132 inhibitor
IDH2 inhibitor
placebo
+ anthracycline
Acute myeloid leukaemia
Myelodysplastic syndrome
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12616001112459
Curative
Phase 1 / Phase 2
Recruiting
Efficacy and Safety of Folfirinox as Neoadjuvant Chemotherapy for Resectable Gastric or Gastroesophageal junction adenocarcinoma- a run- in pilot followed by Phase 2 comparison between ECF and FOLFIRINOX –
FIG
study
Cisplatin
Epirubicin
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
anthracycline
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
+ anthracycline
Gastric adenocarcinoma
Gastroesophageal junction adenocarcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
ACTRN12616000445471
Haem
Phase 1 / Phase 2
Recruiting
A phase Ib clinical evaluation of Venetoclax in combination with chemotherapy in older patients with Acute Myeloid Leukemia (
CAVEAT
)
BCL2 inhibitor
+ anthracycline
Acute myeloid leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06161025
Advanced
Phase 2 / Phase 3
Active not recruiting
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (
DS6000-109
)
anti-CDH6 antibody-drug conjugate
+ anthracycline
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NCT06091865
Haem
Phase 3
Active not recruiting
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (
OLYMPIA-3
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
+ anthracycline
Diffuse large B-cell lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
NCT05740566
Advanced
Phase 3
Active not recruiting
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (
DeLLphi-304
)
bispecific T-cell engager,DLL3-targeting
+ anthracycline
Small-cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
NCT05613088
Advanced
Phase 2
Active not recruiting
A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (
CA116-001
)
anti-FR-alpha antibody-drug conjugate
+ anthracycline
Cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT05578976
Haem
Phase 3
Active not recruiting
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (
EPCORE-DLBCL-2
)
bispecific T-cell engager,CD20-targeting
+ anthracycline
Diffuse large B-cell lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Hollywood Private Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05218499
Advanced
Phase 2 / Phase 3
Active not recruiting
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma (
1403-0008
)
MDM2 inhibitor
anthracycline
Liposarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Glandore - Ashford Cancer Centre
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ anthracycline
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (29)
Active not recruiting (6)
Not yet recruiting (1)
Status unknown (1)
Recruitment Country and State
NSW (30)
VIC (27)
QLD (19)
WA (18)
SA (14)
NZ (9)
TAS (3)
NT (1)
ACT (1)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (5)
Phase 2 (3)
Phase 2 / Phase 3 (3)
Phase 3 (19)
Trial Type
Advanced (18)
Haem (16)
Curative (3)
Cancer Therapy Class
CD20
32%
Trop2
11%
PD-1
11%
PD-1/PD-L1
11%
cereblon
8%
CD79b
8%
BCL2
8%
BTK
5%
CD19
5%
CRAF
5%
FAK
5%
RAF
5%
FR-alpha
5%
KIT
5%
PDGFR
5%
VEGFR
5%
ALK
5%
ROS1
5%
B7H3
3%
PARP
3%
PD-L1
3%
BRAF
3%
MEK
3%
pan-RAF
3%
oestrogen axis
3%
DNA methyltransferase
3%
KMT2A
3%
VEGF
3%
WEE1
3%
GD2
3%
CD22
3%
FGFR
3%
FGFR1
3%
FGFR1/2/3
3%
FGFR2
3%
FGFR3
3%
FGFR4
3%
RET
3%
IDH1
3%
IDH1 R132
3%
IDH2
3%
CDH6
3%
DLL3
3%
MDM2
3%
ATR
3%
BCR-ABL1
3%
CDK4
3%
CDK6
3%
EGFR
3%
FLT3
3%
JAK1
3%
JAK2
3%
MET
3%
PDGFRA
3%
PI3K
3%
SMO
3%
SRC
3%
YES1
3%
mTOR
3%
mTORC1
3%
mTORC2
3%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (11)
2050 - Camperdown - Chris O'Brien Lifehouse (10)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (8)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (8)
3168 - Clayton - Monash Medical Centre (7)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (7)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (7)
3004 - Melbourne, Southbank - Alfred Health (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
4102 - Woolloongabba - Princess Alexandra Hospital (5)
5042 - Bedford Park - Flinders Medical Centre (5)
2031 - Randwick - Prince of Wales Hospital (5)
2170 - Liverpool - Liverpool Hospital (5)
3199 - Frankston - Peninsula Health Frankston Hospital (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
2145 - Westmead - The Children's Hospital at Westmead (4)
2305 - New Lambton Heights - John Hunter Children's Hospital (4)
6009 - Perth - Perth Children's Hospital (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
3002 - East Melbourne - Epworth Freemasons (3)
2139 - Concord - Concord Repatriation General Hospital (3)
7000 - Hobart - Royal Hobart Hospital (3)
6000 - Perth - Royal Perth Hospital (3)
3052 - Parkville - Royal Children's Hospital Melbourne (3)
4101 - South Brisbane - Queensland Children's Hospital (3)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
3066 - Epping - Northern Hospital (2)
2031 - Randwick - Sydney Children's Hospital (2)
NZ.1023 - Grafton - Starship Children's Hospital (2)
2228 - Miranda - Southside Cancer Care Centre (1)
2259 - Wyong - Wyong Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2109 - North Ryde - Macquarie University Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
2217 - Kogarah - St George Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
6005 - West Perth - Perth Blood Institute (1)
6009 - Nedlands - Hollywood Private Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Lymphoma
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Leukaemia
Gynaecological cancer
Ovarian cancer
Sarcoma
Lymphoid leukaemia
Thoracic cancer
Epithelial Ovarian Cancer
Peritoneal cancer
Acute myeloid leukaemia
Myeloid leukaemia
Chronic lymphocytic leukaemia
Endometrial cancer
Breast cancer
Carcinoma
Lung cancer
Neuroendocrine carcinoma
Respiratory tract cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Ovarian adenocarcinoma
Ovarian serous carcinoma
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Primary peritoneal serous carcinoma
Liposarcoma
Soft tissue sarcoma
Mantle cell lymphoma
Low-grade serous ovarian cancer
High-grade serous ovarian cancer
Platinum resistant ovarian cancer
Small Lymphocytic Lymphoma
Primary fallopian tube serous carcinoma
Wilms tumour
Neuroblastic tumour
Neuroblastoma
Neurological cancer
Peripheral nervous system tumour
Leiomyosarcoma
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Myelodysplastic syndrome
Myeloproliferative neoplasm
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Gastrointestinal cancer
Oesophageal cancer
Upper gastrointestinal cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy